Advertisement

Clinical Rheumatology

, Volume 34, Issue 1, pp 61–69 | Cite as

Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis

  • D. Windschall
  • T. Müller
  • I. Becker
  • G. Horneff
Original Article

Abstract

The approval of etanercept for the treatment of the juvenile idiopathic arthritis (JIA) categories extended oligoarthritis (ExtOA), enthesitis-related arthritis (ERA) and psoriasis arthritis (PsA) was recently added to the approval for the treatment of polyarticular-course JIA (PA). This study aims to evaluate the efficacy and safety of etanercept in a large number of patients with the additional JIA categories. The Biologika in der Kinderrheumatologie (BIKER) registry documents baseline demographics, clinical characteristics and disease activity parameters. Efficacy was determined using the PedACR 30/50/70 response criteria and the Juvenile Arthritis Disease Activity Score (JADAS)-10. Safety assessments were based on adverse events’ reports. Until December 2012, a total of 1,678 JIA patients, incorporating 238 ERA, 315 ExtOA and 127 PsA patients were included. JADAS-10 demonstrated marked improvement compared to baseline after 3 to 24 months in ExtOA [16.1 ± 7.6 (baseline), 5.1 ± 5.2 (3 months), 3.0 ± 3.5 (24 months)]; ERA (15.3 ± 7.2, 4.4 ± 4.7, 4.0 ± 4.9) and PsA (14.7 ± 6.4, 5.0 ± 4.6, 5.3 ± 6.4). Compared to patients with PA, the rate of serious adverse events [relative risk (RR) 1.39 (0.95–2.03, p = 0.08)] and nonserious [1.18 (1.02–1.35; p = 0.03)] adverse events were elevated. The rate of uveitis flares was significantly higher in PsA (3.3/100 patient-years), ExtOA (2.8/100 patient-years) and ERA (2.7/100 patient-years) than in rheumatoid factor (RF)-negative polyarticular JIA (1.3/100 pat.yrs) or RF-positive polyarticular JIA (0.27/100 patient-years). Reports on chronic inflammatory bowel disease were numerically more frequent in ExtOA, ERA and PsA. Administration of etanercept in patients with the JIA categories ExtOA, ERA and PsA is safe and very efficacious in children. Attention should be paid to the occurrence of extraarticular autoimmunopathies.

Keywords

Efficacy Etanercept Juvenile idiopathic arthritis Safety Selected categories 

Notes

Acknowledgments

The authors would like to thank all rheumatology centres in Germany and Austria participating in the BIKER registry.

Conflict of interest

DW declares grant/research support from Pfizer. GH declares grant/research support from Pfizer, AbbVie and Roche. TM and IB declare no competing interests.

Funding

The BIKER registry is funded by an unrestricted grant from Abbott/Abbvie, Wyeth/Pfizer and Roche/Chugai. The sponsors had no influence on study design, data analysis and/or manuscript writing. The submitted manuscript has not been discussed with the sponsors. Publication was not established as a contractual part of the sponsoring.

References

  1. 1.
    Atteno M, Peluso R, Costa L et al (2010) Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheum 29(4):399–403CrossRefGoogle Scholar
  2. 2.
    Gorman J, Sack K, Davis J (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor (alpha). N Engl J Med 346(18):1349–1356PubMedCrossRefGoogle Scholar
  3. 3.
    Mease P, Kivitz A, Burch F, Siegel E et al (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50(7):2264–2272PubMedCrossRefGoogle Scholar
  4. 4.
    Mease P, Woolley JM, Singh A, Tsuji W, Dunn M, Chiou C (2010) Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis. J Rheumatol 37(6):1221–1227PubMedCrossRefGoogle Scholar
  5. 5.
    Wanke LA, Mease P, Gottlieb A, Burge D (2004) Sustained improvement in activities of daily living and vitality in patients with psoriatic arthritis treated with etanercept. J Am Acad Derm 50(3):145CrossRefGoogle Scholar
  6. 6.
    Dueckers G, Guellac N, Arbogast M et al (2011) Evidence and consensus based treatment guidelines 2010 for juvenile idiopathic arthritis by the German Society of Pediatric Rheumatology. Klin Padiatr 223(6):386–394PubMedCrossRefGoogle Scholar
  7. 7.
    Giannini EH, Ilowite NT, Lovell DJ et al (2009) Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 60(9):2794–2804PubMedCrossRefGoogle Scholar
  8. 8.
    Halbig M, Horneff G (2009) Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept. Rheumatol Int 30(2):229–238PubMedCrossRefGoogle Scholar
  9. 9.
    Henrickson M, Reiff A (2004) Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. J Rheumatol 31(10):2055–2061PubMedGoogle Scholar
  10. 10.
    Horneff G, Schmeling H, Biedermann T et al (2004) The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 63(12):1638–1644PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Horneff G, Burgos-Vargas R, Constantin T et al (2013) Efficacy and safety of open label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: part 1(week 12) of the CLIPPER study. Ann Rheum Dis. doi: 10.1136/annrheumdis-2012-203046 PubMedCentralPubMedGoogle Scholar
  12. 12.
    Prince FH, Twilt M, ten Cate R et al (2009) Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 68(5):635–641PubMedCrossRefGoogle Scholar
  13. 13.
    Foeldvari I, Ruperto N, Dressler F et al (2001) The German version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 19(4 Suppl 23):71–75Google Scholar
  14. 14.
    Consolaro A, Ruperto N, Bazso A et al (2009) Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 61(5):658–666PubMedCrossRefGoogle Scholar
  15. 15.
    Horneff G, Foeldvari I, Minden K, Moebius D, Hospach T (2011) Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology (Oxford) 50(1):230–236CrossRefGoogle Scholar
  16. 16.
    Kemper AR, Van Mater H, Coeytaux R, Williams JW Jr, Sanders G (2012) Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis. BMC Pediatr 12:29PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis. Technology Appraisal No.35 National Institute for Health and Care Excellence. 1-24 March 2002 (review January 2005). www.nice.org.uk
  18. 18.
    Lovell DJ, Giannini EH, Reiff A et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342:763–769Google Scholar
  19. 19.
    Paller A, Siegfried E, Eichenfield L et al (2010) Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Derm 63(5):762–768PubMedCrossRefGoogle Scholar
  20. 20.
    Sticherling M, Minden K, Küster RM, Krause A, Borte M (2007) Psoriasis und Psoriasisarthritis im Kindes- und Jugendalter. Zeitschr Rheum 66(4):349–354Google Scholar
  21. 21.
    Tse S, Burgos-Vargas R, Laxer RM (2005) Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum 52(7):2103–2108PubMedCrossRefGoogle Scholar
  22. 22.
    Horneff G, Fitter S, Foeldvari I et al. Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther 2012 Oct 24;14(5):R230Google Scholar
  23. 23.
    Grom A, Murray KJ, Luyrink L et al (1996) Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum 39(10):1703–1710PubMedCrossRefGoogle Scholar
  24. 24.
    Otten MH, Prince FH, Twilt M et al (2011) Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis—data from the dutch arthritis and biologicals in children register, 1999-2010. J Rheumatol 38(10):2258–2263PubMedCrossRefGoogle Scholar
  25. 25.
    Heiligenhaus A, Niewerth M, Ganser G, Heinz C, Minden K (2007) Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford) 46(6):1015–1019CrossRefGoogle Scholar
  26. 26.
    Winterhalter S, Niehues T (2008) TNFalpha-blocking agents or conventional immunosuppressive drugs in the therapy of children with uveitis?—an evidence based approach. Klin Padiatr 220(6):342–347PubMedCrossRefGoogle Scholar
  27. 27.
    Saurenmann RK, Levin V, Feldman BM, Laxer RM, Schneider R, Silverman ED (2006) Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFα agents. J Pediatr 149:833–836PubMedCrossRefGoogle Scholar
  28. 28.
    van Dijken TD, Vastert SJ, Gerloni VM, Pontikaki I, Linnemann K, Girschick H, Armbrust W, Minden K, Prince FH, Kokke FT, Nieuwenhuis EE, Horneff G, Wulffraat NM (2011) Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 38(7):1441–1446PubMedCrossRefGoogle Scholar
  29. 29.
    Klein A, Kaul I, Foeldvari I, Ganser G, Urban A, Horneff G (2011) Efficacy and safety of oral and parenteral methotrexate therapy in children with JIA: an observational study with patients from the German methotrexate registry. Arthritis Care Res 63:465–482CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2014

Authors and Affiliations

  • D. Windschall
    • 1
  • T. Müller
    • 2
  • I. Becker
    • 3
  • G. Horneff
    • 4
  1. 1.Department of PediatricsAsklepios Hospital WeissenfelsWeissenfelsGermany
  2. 2.Department for Pediatric RheumatologyMartin-Luther-University Halle-WittenbergHalleGermany
  3. 3.Institute of Medical Statistics, Informatics and EpidemiologyUniversity of CologneCologneGermany
  4. 4.Centre for Pediatric Rheumatology, Department of PediatricsAsklepios Klinik Sankt AugustinSankt AugustinGermany

Personalised recommendations